PharmaTher(OTC) PHRRF

Market Cap$3.49M

Since IPO (2020)-79%

5 Year-95%

1 Year-86%

1 Month-2%

$0.04

+1.59%

+0.00Today

PharmaTher last closing stock price
Metric	Price	Date
Last close	USD 0.04	2026-09-04

PharmaTher stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-10.51%	USD 0.04	2026-08-28
1 month	-1.56%	USD 0.04	2026-08-05
3 month	-13.54%	USD 0.04	2026-06-05
Year to date	-45.16%	USD 0.07	2025-12-31
1 year	-85.79%	USD 0.27	2025-09-04
3 year	-60.01%	USD 0.10	2023-09-05
5 year	-95.08%	USD 0.78	2021-09-03
Since inception	-78.66%	USD 0.18	2020-11-25

PharmaTher Financials at a Glance

Market Cap

$3.49M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$1.10M

EPS (TTM)

-$0.01

P/E Ratio

-4.36

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.04

Volume

77,773

Open

$0.04

Price

$0.04

Volume

77,773

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.03 - $0.30

Estimated Earnings Date

Sep 24, 2026

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.04

Volume

77,773

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.03 - $0.30

Estimated Earnings Date

Sep 24, 2026

PHRRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaTher

PharmaTher Holdings Ltd. is a biotechnology firm focused on developing innovative psychedelic treatments for mental health issues, neurological diseases, and chronic pain. The company is advancing several products through clinical trials, aiming to address significant unmet medical needs.

Products and Services

Intravenous ketamine injection for Parkinson's disease and ALS
Ketamine Patch for depression and pain-related conditions
PHARMAPATCH for transdermal delivery of psychedelic compounds

Growth Outlook

Strong pipeline with multiple products in Phase II and III clinical trials
Strategic partnerships enhancing development capabilities and market reach
Increasing interest in psychedelic therapies driving market potential

Financial Highlights

Recent quarterly net income of -$2,364, reflecting ongoing R&D investments
Cash and short-term investments of $861,389, providing operational runway
Trailing twelve months (TTM) revenue of $0, focusing on product development

PharmaTher Holdings Ltd. is positioned in a rapidly evolving sector, with a focus on psychedelic therapies that have gained traction in recent years. The company's commitment to research and development is evident in its substantial investments, which are reflected in its recent financials. Despite reporting a net loss, the available cash reserves indicate a capacity to sustain operations while advancing its clinical trials. The strategic partnerships established by PharmaTher further enhance its potential for growth and innovation in the biotechnology landscape. As the market for psychedelic treatments expands, PharmaTher's unique offerings may provide significant opportunities for future success.

AI Generated • Aug 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Fabio Chianelli

Website

www.pharmather.com

Headquarters

Toronto, ON M5C 1P1, CA

PHRRF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-155.46%

Return on Capital

-156.50%

Return on Assets

-103.41%

Earnings Yield

-22.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.49M

Shares Outstanding

91.02M

Volume

77.77K

Avg. Volume

148.15K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$1.29M

EBITDA

-CA$1.42M

Operating Cash Flow

-CA$680.28K

Capital Expenditure

CA$3.00

Free Cash Flow

-CA$680.28K

Cash & ST Invst.

CA$861.39K

Total Debt

CA$0.00

PharmaTher Performance Analysis

PharmaTher annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-05-31	CAD 0	N/A
2023	2023-05-31	CAD 0	N/A
2024	2024-05-31	CAD 0	N/A
2025	2025-05-31	CAD 0	N/A

PharmaTher sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-05-31	N/A
Q1	2025-08-31	N/A
Q2	2025-11-30	N/A
Q3	2026-02-28	N/A

PharmaTher annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-05-31	CAD -0.04	N/A
2023	2023-05-31	CAD -0.05	39.0%
2024	2024-05-31	CAD -0.03	-52.1%
2025	2025-05-31	CAD -0.01	-52.5%

PharmaTher sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2025-05-31	-76.2%
Q1	2025-08-31	35.1%
Q2	2025-11-30	43.7%
Q3	2026-02-28	100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$3.49M

N/A

Market Cap/Employee

$698.84K

N/A

Employees

N/A

Net Income

-CA$2.36K

+99.4%

EBITDA

-CA$212.43K

+40.6%

Quarterly Fundamentals

Name

Q3 2026YOY CHG

Total Cash

CA$861.39K

-33.3%

Total Debt

CA$0.00

N/A

Accounts Receivable

CA$8.31K

-48.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$0.00

N/A

Return on Assets

-1.03%

N/A

Return on Invested Capital

-2.41%

N/A

Free Cash Flow

CA$90.78K

+134.7%

Operating Cash Flow

CA$90.78K

+134.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LIANYLianBio

LIANYLianBio$0.04-2.50%

BIXTBioxytran, Inc.

BIXTBioxytran, Inc.$0.02+4.95%

CUBTCurative Biotechnology, Inc.

CUBTCurative Biotechnology, Inc.$0.75-16.67%

THERTheralink Technologies, Inc.

THERTheralink Technologies, Inc.$0.00+0.00%

NSHSFNanoSphere Health Sciences Inc.

NSHSFNanoSphere Health Sciences Inc.$0.01+0.00%

BETRFBetterLife Pharma Inc.

BETRFBetterLife Pharma Inc.$0.22+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15-0.12%

NVDANvidia

NVDANvidia$230.36+0.01%

PATHUiPath

PATHUiPath$15.19-0.17%

INTCIntel

INTCIntel$95.80+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.13+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.74-0.02%

TSLATesla

TSLATesla$354.08-0.06%

Questions About PHRRF

What is the current price of PharmaTher?

PharmaTher is trading at $0.04 per share.

What is the 52-week range for PharmaTher?

Over the past 52 weeks, PharmaTher has traded between $0.03 and $0.30.

How much debt does PharmaTher have?

As of the most recent reporting period, PharmaTher reported total debt of CA$0.00.

How much cash does PharmaTher have on hand?

PharmaTher reported CA$582.76K in cash and cash equivalents in its most recent financial results.

What is PharmaTher’s dividend yield?

PharmaTher does not currently have a dividend yield.

PharmaTher(OTC) PHRRF

PharmaTher Financials at a Glance

PHRRF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About PharmaTher

PHRRF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

PharmaTher Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PHRRF

What is the current price of PharmaTher?

What is the 52-week range for PharmaTher?

How much debt does PharmaTher have?

How much cash does PharmaTher have on hand?

What is PharmaTher’s dividend yield?

Premium Investing Services